Physician profile
Anna K Menze
NPI 1831547124
$7,858.51
in general payments reported to CMS, 2019-2025
48 companies · $941 in 2025
The $941 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $1,054 · 2021: $1,473 · 2022: $1,138 · 2023: $1,117 · 2024: $1,657 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,715.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,644.85 | 2021-2025 | |
| Novo Nordisk INC | $925.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $819.09 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $587.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $557.96 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $551.01 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $218.24 | 2020-2024 | Steglatro, Belsomra, Steglujan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.17 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $186.06 | 2019-2025 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $164.31 | 2020-2024 | Trintellix |
| Amgen INC. | $156.28 | 2019-2025 | Repatha, Repatha, Otezla |
| Corium, LLC | $152.51 | 2022-2025 | Azstarys |
| Stryker Corporation | $145.17 | 2019 | |
| Medtronic, INC. | $139.77 | 2022 | |
| Abbott Laboratories | $106.56 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Menze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.